Times Square Capital Management, LLC Krystal Biotech, Inc. Transaction History
Times Square Capital Management, LLC
- $6.51 Billion
- Q4 2024
A detailed history of Times Square Capital Management, LLC transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Times Square Capital Management, LLC holds 158,868 shares of KRYS stock, worth $28.6 Million. This represents 0.38% of its overall portfolio holdings.
Number of Shares
158,868
Previous 114,222
39.09%
Holding current value
$28.6 Million
Previous $20.8 Million
19.82%
% of portfolio
0.38%
Previous 0.32%
Shares
6 transactions
Others Institutions Holding KRYS
# of Institutions
300Shares Held
24.3MCall Options Held
388KPut Options Held
233K-
Black Rock Inc. New York, NY3.95MShares$711 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.88MShares$518 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.63MShares$473 Million6.0% of portfolio
-
State Street Corp Boston, MA1.28MShares$230 Million0.01% of portfolio
-
Capital World Investors Los Angeles, CA879KShares$158 Million0.02% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $4.62B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...